Microfluidics-technology enabled double-emulsion system for thermal insulation of heat-sensitive medications

我们正在与生物技术公司VivaVax Inc.合作开发一种新的疫苗交付模式。**目前，VivaVax正在为主要疫苗MMRII(美国默克)和Gardasil 13(美国默克)开发交付解决方案，这两种疫苗在全球范围内用于预防腮腺炎、麻疹、风疹和人乳头瘤病毒的感染。VivaVax疫苗交付模式的主要创新是能够**在外部环境温度变化时**保持疫苗温度近乎恒定。VivaVax**通过开发一种专有的热保护配方来实现这一点，这种配方是在多糖骨架上的两亲性**聚合物结构的混合物，已显示出乳化稳定性和生物降解性。**该公司面临的挑战之一是，由于传统的高压均质制造**工艺，每个**封装疫苗包装的一致性和质量存在很大的不确定性。对于这个NSERC Engage项目，VivaVax将与我的研究团队合作，应用创新的**微流体技术，在**热防护配方的薄膜内创建疫苗的多相胶囊，从而使疫苗能够在单分散和高度一致的**双乳状液中得到保护。

We are working with the biotechnology company, VivaVax Inc., to develop a novel vaccine delivery model.**Currently, VivaVax is developing delivery solutions for the primary vaccines MMRII (Merck, United States)**and Gardasil 13 (Merck, United States), which are used globally to prevent infections of mumps, measles,**rubella, and human papillomavirus. The main innovation in VivaVax's vaccine delivery model is its ability to**maintain a near constant vaccine temperature while the external environmental temperature changes. VivaVax**achieves this by developing a proprietary thermal-protective formulation that is a mixture of amphiphilic**polymer constructs on poly-saccharide backbones, which have shown emulsion stability and biodegradability.**One of the company's challenges has been the large uncertainties in the consistency and quality of each**encapsulated vaccine package that is a result of the the traditional high pressure homogenization manufacturing**processes. For this NSERC Engage project, VivaVax will work with my research group to apply innovative**microfluidics technology to create multi-phasic encapsulations of the vaccines, within thin films of the**thermal-protective formulation, so that the vaccines can be protected in monodisperse and highly consistent**double emulsions.